IL-15 polymer conjugate enhances liso-cel response in R/R LBCL

Promising CAR-T cell expansion and persistence with the addition of NKTR-255 to lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Fast production, low high-grade toxicity with CAR-T cell therapy in R/R NHL

ATALANTA-1 study shows a manageable safety profile for the CAR T-cell therapy GLPG5101 for patients with relapsed/refractory non-Hodgkin lymphoma

‘High response rates’ with rapcabtagene autoleucel in R/R DLBCL

The CAR-T cell therapy rapcabtagene autoleucel shows high and durable complete response rates in patients with relapsed/refractory DLBCL.